Cliff Asness's COLL Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 101,254 shares of Collegium Pharmaceutical, Inc. (COLL) worth $4.69 M, representing 0.00% of the portfolio. First purchased in 2018-Q2, this long-term strategic position has been held for 31 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in COLL, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2020, adding 82,485 shares. Largest reduction occurred in Q3 2022, reducing 75,227 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Collegium Pharmaceutical (COLL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Collegium Pharmaceutical (COLL) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +14,070 | Add 16.14% | 101,254 | $46.30 |
| Q3 2025 | -3,200 | Reduce 3.54% | 87,184 | $34.99 |
| Q2 2025 | -16,988 | Reduce 15.82% | 90,384 | $29.57 |
| Q1 2025 | -46,844 | Reduce 30.38% | 107,372 | $29.85 |
| Q4 2024 | +25,206 | Add 19.54% | 154,216 | $28.65 |
| Q3 2024 | +27,054 | Add 26.53% | 129,010 | $38.64 |
| Q2 2024 | -7,170 | Reduce 6.57% | 101,956 | $32.20 |
| Q1 2024 | +3,960 | Add 3.77% | 109,126 | $38.82 |
| Q4 2023 | +732 | Add 0.70% | 105,166 | $30.78 |
| Q3 2023 | +55,138 | Add 111.85% | 104,434 | $22.35 |
| Q2 2023 | +33,912 | Add 220.44% | 49,296 | $21.49 |
| Q1 2023 | +5,611 | Add 57.41% | 15,384 | $23.99 |
| Q4 2022 | +9,773 | New Buy | 9,773 | $23.20 |
| Q3 2022 | -75,227 | Sold Out | 0 | $0.00 |
| Q2 2022 | +40,806 | Add 118.55% | 75,227 | $17.72 |
| Q1 2022 | +20,265 | Add 143.15% | 34,421 | $20.37 |
| Q4 2021 | +1,008 | Add 7.67% | 14,156 | $18.65 |
| Q3 2021 | -468 | Reduce 3.44% | 13,148 | $19.77 |
| Q2 2021 | +931 | Add 7.34% | 13,616 | $23.65 |
| Q1 2021 | -24,253 | Reduce 65.66% | 12,685 | $23.73 |
| Q4 2020 | -19,550 | Reduce 34.61% | 36,938 | $20.03 |
| Q3 2020 | -9,928 | Reduce 14.95% | 56,488 | $20.82 |
| Q2 2020 | -27,566 | Reduce 29.33% | 66,416 | $17.50 |
| Q1 2020 | +82,485 | Add 717.45% | 93,982 | $16.33 |
| Q4 2019 | +11,497 | New Buy | 11,497 | $20.61 |
| Q3 2019 | -24,334 | Sold Out | 0 | $0.00 |
| Q2 2019 | +24,334 | New Buy | 24,334 | $13.15 |
| Q1 2019 | -17,335 | Sold Out | 0 | $0.00 |
| Q4 2018 | -3,312 | Reduce 16.04% | 17,335 | $17.19 |
| Q3 2018 | -3,849 | Reduce 15.71% | 20,647 | $14.72 |
| Q2 2018 | +24,496 | New Buy | 24,496 | $23.84 |
Cliff Asness's Collegium Pharmaceutical Investment FAQs
Cliff Asness first purchased Collegium Pharmaceutical, Inc. (COLL) in Q2 2018, acquiring 24,496 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Collegium Pharmaceutical, Inc. (COLL) for 31 quarters since Q2 2018.
Cliff Asness's largest addition to Collegium Pharmaceutical, Inc. (COLL) was in Q1 2020, adding 93,982 shares worth $1.54 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 101,254 shares of Collegium Pharmaceutical, Inc. (COLL), valued at approximately $4.69 M.
As of the Q4 2025 filing, Collegium Pharmaceutical, Inc. (COLL) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Collegium Pharmaceutical, Inc. (COLL) was 154,216 shares, as reported at the end of Q4 2024.